Canada CAR-T Cell Therapy Market By Drug Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), By End User (Hospitals, Cancer Treatment Centers), By Region, Competition Forecast and Opportunities, 2018-2028F
Published on: 2024-11-25 | No of Pages : 320 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Canada CAR-T Cell Therapy Market By Drug Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), By End User (Hospitals, Cancer Treatment Centers), By Region, Competition Forecast and Opportunities, 2018-2028F
Favorable Regulatory Environment
Increasing Prevalence of Cancer
Collaboration between Industry and Research Institutions
Growing Investment in CAR-T Cell Therapy
Improving Treatment Outcomes
Recent Developments
- Kymriah, developed by Novartis, received Health Canada approval in 2018 for the treatment of pediatric and young adult patients up to 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) that is refractory or in a second or later relapse. It was the first CAR-T cell therapy to be approved in Canada.
- Yescarta, developed by Gilead Sciences, received Health Canada approval in 2019 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Market Segmentation
Market Players
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Drug Type By Indication By End User By Region |
| Regional scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key companies profiled | Kolon TissueGene Inc, JCR Pharmaceuticals Co Ltd, Medipost Co Ltd, Pharmicell Co Ltd, Anterogen Co Ltd, Bristol-Myers Squibb Canada Inc, Novartis Pharmaceuticals Canada Inc |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |